 |  |  |  |  |
|---|---|---|---|---|
 |  |  |  |  |
 |
高雄市癌症及血管防治協會 (Kaohsiung Cancer and Vessel Health Association)
WELCOMES YOU
Welcome to the official website of 高雄市癌症及血管防治協會 (Kaohsiung Cancer and Vessel Health Association). As a leader in the healthcare professional, we believe in setting the bar high, with an unwavering commitment to our patients as well as outstanding and unparalleled medical service. We go above and beyond to make sure all of our patients’ needs are not only met, but exceeded. For more information about us, check out our website and get in touch today.
EDUCATIONAL ACTIVITIES
See Our Activity Portfolio
Since we started our association in 2019, we’ve been expanding our educational portfolio of projects, working with a variety of healthcare professionals, biologic institutes, biotech and pharmacuetical companies all over Taiwan and south region like Kaohsiung. Below you will find some of the events we’ve hold and collaborated with. Take a look at what we’ve worked on together, and feel free to contact us if you would like to work with our team as well.
<南區乳癌研討會>
A Successful Collaboration
2021/10/02 Sat. 2:30pm-6:30pm at 漢神巨蛋
Agenda
Opening
Consistent superior overall survival in pre-menopausal MBC
Transforming 1st line treatment for HR+/HER2- post-menopausal mBC
Coffee Break
Sequential therapy after first line treatment in mBC
The role of PI3K inhibitor in treatment of post-menopausal hormone receptor-positive mBC
Panel discussion
Closing
<南區乳癌治療研討會>
Professional Guidance
2022/6/25 Sat. 3:00pm-6:15pm at 漢神巨蛋
Agenda
Opening
Consistent OS benefit and good QoL with CDK4/6 inhibitors in HR+/HER2- mBC treatment
Updated overview of PI3K inhibitors in HR+/HER2- advanced breast cacner
Coffee Break
The application of genetic biomarkers in clinical decisions
Clinical experience in HR+/HER2- mBC treatment strategy after 1L treatment progression
Closing
<乳癌暨癌症治療研討會>
Creative Synergy
2022/12/17 Sat. 2:30pm-6:00pm at H2O 水京棧國際酒店2樓宴會廳
Agenda
Opening
The Changing Treatment Landscape for HR+/HER2- aBC with Consistent OS results_2022 Update
Transforming 1st Line Treatment Landscape for HR+/HER2- premenopausal mBC
Coffee Break
Overview of PI3K inhibitors in PIK3CA-mutated HR+/HER2- Advanced Breast Cancer
Fulvestrant Selective Estrogen Receptor Degrader in Advanced Breast Cancer
Consistent OS benefit and good QoL with CDK4/6 inhibitors in HR+/HER2- mBC treatment
Updated overview of PI3K inhibitors in HR+/HER2- advanced breast cacner
Closing
IN DEPTH MEDICAL KNOWLEDGE
Truly Top-Notch
Go with us to explore more scientific informaiton, healthcare education, update medical program, and international cancer treatment guidelines together!